Back

Introduction: epidemiological data and current evidence of androgen deprivation therapy associated cardiovascular effects

19 June 2026 (15:30 - 15:40)
Organised by: Logo
Congress Presentation Part of: Androgen deprivation therapy in prostate cancer and cardiovascular risk: mechanistic and clinical considerations Cardiovascular Toxicity of Cancer Therapies Open Access ESC Cardio-Oncology 2026 Council of Cardio-Oncology

About the speaker

Photo
Professor Sebastian Szmit

CMKP & National Research Institute of Oncology, Warsaw (Poland)

3 More presentations in this session

Presentation thumbnail
Cardiovascular effects associated with androgen deprivation therapy: current mechanistic understanding, clinical relevance, and limitations
Doctor B. Terol (Madrid, ES)
Presentation thumbnail
Differential effects of androgen deprivation therapy modalities on platelet phenotype: results from an exploratory clinical study
Doctor A. Beitzen Heineke (Hamburg, DE)
Presentation thumbnail
Conclusion

Access the full session

Session thumbnail
Androgen deprivation therapy in prostate cancer and cardiovascular risk: mechanistic and clinical considerations

The Event

Event poster

ESC Cardio-Oncology 2026

19 June 2026 15:30 CET
You may be interested in
thumbnail
Congress Presentation
Androgen deprivation therapy with agonists of GnRH: cardiovascular adverse events and comorbidity considerations in patients with prostate cancer
27 August 2021
thumbnail
Webinar
Injectable therapies for cardiovascular disease: optimising their use in practice - experiences from the UK and Italy
18 March 2022
thumbnail
ESC Journals
Breast cancer and cardiovascular health
25 September 2024
thumbnail
Congress Presentation
Sex hormones as markers of cardiovascular organ damage in women with overweight and obesity
30 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources